Newsletter · 2026-09-18 · Ashutosh Agarwal

Biotech Rallies as China Becomes Pharma's Discovery Engine - The Healthcare Pulse: Weekly Podcast Intelligence Brief - Week of September 18, 2026

The Healthcare Pulse weekly podcast intelligence brief for the week of September 18, 2026. Money rotated back into biotech behind a working cancer vaccine (Moderna and Merck) and a first-ever pancreatic-cancer drug (Revolution Medicines), while podcasts debated whether China has become pharma's real discovery engine, why the big heart-drug trials failed, and how obesity drugs are being judged on muscle preservation rather than pounds lost.

The Healthcare Pulse: Weekly Podcast Intelligence Brief

Week of September 18, 2026: Biotech Rallies as China Becomes Pharma's Discovery Engine

This Week at a Glance

Last week healthcare was a story about failure: three big heart-drug trials collapsed and Novartis had its worst day on record. This week the mood flipped. Money started flowing back into biotech, chasing a genuine science breakthrough (a cancer vaccine that works), while investors quietly wrestled with a bigger question: is the future of the drug industry being built in China?

A few threads ran through nearly every podcast and news feed:

• A cancer vaccine kicked off a biotech rally, and the debate is whether it's real. Moderna's personalized melanoma vaccine (with Merck) worked in a late-stage trial, and Revolution Medicines won FDA approval for a pancreatic-cancer drug. Moderna's value more than doubled off the news. One Wall Street Journal columnist's verdict on the frenzy: the science is "revolutionary," but the market is "attributing like a huge future revenue to this drug… I'd be careful with that one."
• China is now openly discussed as pharma's discovery engine. A Bloomberg podcast laid out how Merck's most important experimental cancer drug wasn't invented by Merck, it was licensed from a Chinese company. Somewhere between a third and half of all experimental drugs in the world now come from China. As one drug executive put it, you can "go twice as fast at half the cost" there.
• The obesity race quietly changed its scoreboard. For four years the whole game was one number: how much weight you lose. This week the conversation shifted to the quality of that weight loss: keeping muscle, not just shedding pounds. Eli Lilly showed a new combination hitting 17% weight loss in just 16 weeks.
• The heart-drug wreckage got its post-mortem. Analysts and doctors spent the week arguing over why Novartis's and Novo Nordisk's big cardiovascular trials failed, the molecule, the target, or the trial itself, and what it means for the Amgen and Eli Lilly heart drugs still coming.
• The bill for the obesity boom is landing on insurers and patients. Payers are pulling back GLP-1 coverage, roughly half of people quit the drugs within a year, and a Medicare drug-pricing deadline for a big batch of medicines lands at the end of this month.

Below: the people, the debates, the numbers, and why each matters.

The People Driving the Conversation

David Wehner, Wall Street Journal "Heard on the Street" columnist, on WSJ's Take On the Week (September 13). This was the clearest investor-facing breakdown of the week's biotech rally: the science, the stock math, and where the money is rotating WSJ's Take On the Week.

He explained why cash suddenly moved into biotech: when the giant AI and chip stocks wobbled over the summer, investors went hunting for somewhere else to put money, and beaten-down healthcare looked cheap and "defensive."

On Moderna specifically, he was excited about the science and cautious about the price:

"The rally that we saw… added over $25 to $30 billion. It was like about a $20 billion company before the announcement. It's now a $50 to $60 billion… the market definitely is attributing like a huge future revenue to this drug. And so, you know, I'd be careful with that one."

He was more constructive on Revolution Medicines, whose newly approved pancreatic-cancer drug attacks a target (a family of mutations called RAS) that has stumped researchers for decades:

"There is nothing for pancreatic cancer. It's a deadly, deadly cancer… now they've gotten this drug approved that really extends people's lives… the company has a huge platform of these so-called RAS drugs… this company, which is already now about a $50 billion company, could be one of those biotechs that becomes that sort of Gilead or Amgen that trades at $100 billion one day."

But he made a firm call that it won't get bought: "Revolution Medicine will not get acquired." His reasoning doubles as this year's whole M&A playbook: big drugmakers have stopped doing giant mergers (he noted rumored AstraZeneca/Bristol-Myers talks that "tanked" AstraZeneca's stock) and are instead buying small. His metaphor: "Go to the supermarket when you're not too hungry. Leave a little room… go for those biotech companies that maybe in a year or two will give you that data that will become the next big drug."

Robert Langreth and Amber Tong, Bloomberg biotech reporters, on Big Take Asia (September 15). Their episode made the case that China has become "one of the hottest places in the world for finding promising new medicines" Big Take Asia. The centerpiece: Merck's experimental drug SAC-TMT, now in 17 late-stage trials across lung, breast and other cancers, a drug Merck didn't discover but licensed from China's Sichuan Kelun Biotech, where it was already approved. Their framing of why US giants keep shopping in China:

"Think of some of the big U.S. drug companies. They're sort of like Netflix, a kind of insatiable need for new content. And they found in recent years that China is a great place to go to buy early-stage drugs at a lower price… you can go twice as fast at half the cost in China."

Langreth even reached for the AI comparison, calling an earlier Chinese cancer-drug result a "DeepSeek moment" for pharma, a reference to the moment a cheap Chinese AI model rattled US tech stocks.

Dave Knapp, host of On The Pen (September 15), delivered the week's sharpest explanation of how the obesity race is changing On The Pen GLP-1 News. His argument: for years the industry obsessed over one number, total weight lost, but two people who both drop 50 pounds can have completely different bodies underneath, one losing mostly fat, the other losing a lot of muscle with it. He warned investors to be skeptical of the flashiest trial numbers, with a memorable image:

"The efficacy estimate is like the dating profile, great lighting, perfect angle, maybe even an image that was run through AI first… But the treatment policy estimate is actually closer to who actually shows up for the date."

His investor takeaway: "The next generation of these medications is about the quality of weight loss, the quality of life while you're on the medication."

The BioCentury editorial team (Jeff Cranmer, Simone Fishburn, Steve Usdin, Lauren Martz and Stephen Hansen) on BioCentury This Week Ep. 387 (September 15), put hard numbers on the Novartis wreckage and the industry's deal machine BioCentury This Week. Hansen walked through the three failures in "a little over a week" that wiped out $40 billion of Novartis's value: a CAR-T cell-therapy trial with three patient deaths, the pelacarsen heart-drug miss, and a muscle-disease drug (from the ~$12 billion Avidity takeover) that also failed. On the read-across, recorded midday: Amgen down about 9% ("21 billion") and even trillion-dollar Eli Lilly down 2% ("25 billion"), as one host dryly noted, "That's how maths works."

Martz previewed the firm's annual deals study: 221 deals over the past year among the top 21 drugmakers, up sharply, with pharma "looking to bring on products and technologies that have major disruptive potential."

Brian and the "biotech mafia" hosts on Biotech Hangout Ep. 195 (September 15) gave the most technical read on the heart-drug failures and what's next Biotech Hangout. Brian flagged a warning sign that had made insiders uneasy well before the data: Novartis's trial ran far slower than expected because heart attacks and strokes weren't piling up on schedule:

"When these outcome-based studies, when the rates are mismodeled… my experience is generally that means that study is going to fail… I've almost never seen it where that's wound up benefiting the treatment arm."

He noted the drug that failed was "the least active" of the three big heart drugs targeting the same fat particle (called Lp(a)), knocking it down 70–80% versus the near-total reduction Amgen's and Lilly's newer approaches achieve, leaving open the question of whether the idea is wrong or just this version of it.

The Key Debates

Debate 1: Is the biotech cancer-vaccine rally the real thing, or another pop-and-drop?

• The optimistic case: The science genuinely works. Moderna's personalized melanoma vaccine (a shot custom-built for each patient that trains the immune system to hunt their specific tumor) hit its goal, and Revolution Medicines got a pancreatic-cancer drug approved where "there is nothing" today WSJ's Take On the Week. On The Good News About Cancer (September 15), an oncologist called Revolution's drug a breakthrough in cracking RAS, with "longer overall survival, longer tumor control, greater tumor shrinkage, and substantially better quality of life" versus chemo The Good News About Cancer.
• The cautious case: David Wehner reminded listeners that breakthrough drugs and soaring stocks don't always travel together: BioNTech (COVID vaccine) and Novo Nordisk (the first weight-loss drug) both invented world-changing medicines and then "went through years where they did terribly." His bottom line on Moderna: "I think Moderna will be going up and down for a while," because a lot of future revenue is already priced in.

Debate 2: Is China's rise a threat, an opportunity, or both?

• Opportunity: For US drugmakers staring down patent expirations, cheap and fast Chinese science is a gift, a deep aisle of early-stage drugs to buy. Merck's SAC-TMT is the poster child Big Take Asia.
• Threat: Chinese "fast followers" can produce a rival to a US biotech's drug within a short window of a patent filing (legal, because a small tweak counts as a new approach), squeezing early-stage American companies. And a Chinese-developed drug (from Akeso, licensed to Summit Therapeutics) has already beaten Merck's own mega-blockbuster Keytruda in a head-to-head Chinese trial. Wehner's caveat for investors: those results came from trials "run in China," and "we're still waiting for the critical thing, which is overall survival" (did patients actually live longer), plus the question of whether the results repeat when the trial is rerun in the US.

Debate 3: Why did the big heart-drug trials really fail, and is Amgen next?

• "It might be the trial, not the biology": BioCentury's Lauren Martz laid out three suspects (the target, the molecule, or the trial design) and cautioned "we don't have enough information to determine" which BioCentury This Week. A key nuance: modern patients are already on statins, PCSK9 drugs and GLP-1s, all protecting the heart, which makes it very hard for any new drug to show extra benefit.
• "The read-across is scary": Biotech Hangout's hosts said generalist investors have been peppering them about Amgen, since roughly one in five people carry the genetic trait these drugs target, and Amgen fell about 10% on the read-through Biotech Hangout. Amgen's own heart-drug data (olpasiran) is expected next year; Lilly's may not come until 2029. On Ground Truths (September 14), researchers urged waiting for the final numbers before writing off the whole idea, noting the drug did achieve 70–80% reduction of its target Ground Truths.
• The hedge nobody noticed: BioCentury pointed out Novartis had quietly signed two deals with a Chinese company, Argo Biopharma (paying $160 million and $185 million upfront), for a newer-technology heart drug going after the same target, meaning Novartis may have been protecting itself all along, or "maybe they saw some stuff in the blinded data that they weren't super thrilled with."

Debate 4: Should you measure obesity drugs by pounds lost, or by what kind of pounds?

• The new scoreboard: On The Pen highlighted Scholar Rock's apitegromab (now approved for a rare muscle disease as "Issembled"), which in an obesity study preserved about 55% more lean mass when added to Lilly's tirzepatide On The Pen GLP-1 News. Lilly is chasing the same idea with a muscle-preserving drug (bemagrimab) it bought for around $2 billion. The commercial catch: Issembled launches at about $310,000 a year and must be given by IV, so it's essentially off-limits for everyday weight-loss use.
• The efficiency angle: In the same episode, Lilly showed its new amylin drug eloralentide plus a low 5 mg dose of tirzepatide hitting 17% weight loss in 16 weeks (versus 10% for tirzepatide alone), hinting the company can reach top-tier results at gentler doses. Knapp's read: the industry is starting to compete on tolerability and body composition, not just the headline number.

Debate 5: Can AI actually invent new drugs, or just help around the edges?

• The skeptical view: Wehner pushed back on the popular idea that AI will soon crack cancer, pointing out that the year's actual breakthroughs (Moderna, Revolution) "didn't really have a lot to do with AI." His core constraint: "We still have to test drugs in human bodies… AI can't accelerate that, not yet. So a lot more needs to change" WSJ's Take On the Week. AI is speeding up trial recruitment and diagnosis today, the leap to inventing cures is still years of proof away.

Hot Topics Under Debate

• The oncology data flood. Cancer conferences produced a run of wins that reset several stocks. Johnson & Johnson's PAPILLON trial showed its lung-cancer combination (Rybrevant plus chemo) extending median survival to about 34.3 months versus 27.9 for chemo alone in a specific mutation type (a 43% lower risk of death in the adjusted analysis), described as the longest survival ever reported in that group (MT Newswires, September 14). On BioSpace (September 16), hosts walked through fresh lung-cancer data from the World Conference on Lung Cancer, including Summit and Akeso's drug cutting the risk of death 27% versus Keytruda in a China trial BioSpace. And Oncology Brothers covered the FDA approval of AstraZeneca's camizestrant in advanced breast cancer, which nearly doubled the time before the disease worsened (17 months versus 9) Oncology Brothers.
• Eli Lilly gets a chorus of upgrades. Berenberg upgraded Lilly to Buy with a $1,400 target (from $1,220) on September 15; Goldman Sachs (Buy, $1,371) and Guggenheim (Buy, $1,284) nudged theirs up too. Lilly also closed its AtaiBeckley acquisition (depression drugs) and signed Twist Bioscience and Ginkgo Bioworks onto its AI drug-discovery platform, TuneLab (thefly / MT Newswires, September 11–18).
• UnitedHealth's investors get jumpy about 2028. UBS kept a Buy and $490 target but flagged that Wall Street "had a more nervous reaction to management's conference comments related to MA Stars than the company expected," with "Stars" being the government quality ratings that drive Medicare Advantage payments, here for payment year 2028 (MT Newswires, September 14). UBS still thinks UnitedHealth can deliver mid-teens annual profit growth. Separately, Wells Fargo warned of rising medical-cost pressure across insurers as billing disputes accelerated over the summer.
• Bristol-Myers, Gilead and Amgen quietly advanced. Piper Sandler raised Bristol-Myers to a $82 target (from $75), pointing to three big upcoming milestones: a blood thinner (milvexian), an Alzheimer's-psychosis use for Cobenfy, and a lung-fibrosis drug (September 16). Gilead expanded global access to its twice-yearly (and eventually once-yearly) HIV-prevention shot lenacapavir. The FDA let Amgen cut the required monitoring time for its lung-cancer drug Imdelltra from 22–24 hours down to 6–8, making it far easier for community clinics to use.
• Intuitive Surgical: fallen darling, still not a bargain. On InvestTalk, a host addressed the surgical-robot leader after a ~38% drop this year, and declined to call it cheap: revenue growth has slowed from the mid-20s percent to about 10%, and "just because something has fallen down doesn't necessarily mean it's a value play." Verdict: watch list, not buy list InvestTalk.

Emerging Themes to Watch

• The obesity boom's payer backlash is here. The story has shifted from "how big is the market" to "who's going to pay for it." Massachusetts data showed 112,000 fewer commercially insured residents using a weight-loss GLP-1 after coverage rollbacks, cutting annual spending by about $662 million; PepsiCo and Cigna dropped weight-loss coverage for non-diabetic employees. And roughly half of people quit these drugs within a year, a Rheumnow obesity discussion cited a Danish study of 157,000 patients showing 50% discontinuation at 12 months Rheumnow Podcast. For investors, this pushes the value of Novo and Lilly toward net prices and how long patients stay on, not raw headcount.
• A quieter Medicare pricing clock ticks under all of it. On Squawk Pod (September 8), the discussion noted GLP-1s hitting a $50/month Medicare price (down from over $1,000), with more than 600,000 beneficiaries signing up in two months Squawk Pod. Meanwhile the government's drug-price negotiation program is at a pivotal point: sessions for the third round (which for the first time includes doctor-administered "Part B" drugs) wrapped up September 11, and CMS sends its final price offers by September 30. Ozempic and Wegovy are in the previous round, with negotiated prices taking effect January 1, 2027.
• Muscle-preservation and "body composition" become an investable category. Beyond Scholar Rock and Lilly, The Bio Report (September 16) profiled Wave Life Sciences' approach: an injection given once or twice a year that targeted visceral (belly) fat, showing 14% visceral-fat reduction from a single low dose, positioned to combine with GLP-1s rather than compete The Bio Report. The theme: the next wave of metabolic drugs won't just remove weight, they'll shape what kind of weight comes off.
• Big Pharma's deal machine is running hot, and going small. BioCentury counted 221 deals in a year among the top drugmakers, and the pattern is "tuck-in" acquisitions of promising small companies rather than mega-mergers, plus a wave of licensing from China BioCentury This Week. The biotech IPO market is also having its strongest year since 2021, giving small companies another way to raise cash.
• Next-generation autoimmune drugs in a pill. On Biotech 2050 (September 16), Kymera Therapeutics CEO Nello Mainolfi described an oral drug (a "protein degrader") aimed at the same inflammation pathway as the blockbuster injectable Dupixent, but reaching a far broader group of patients, with Phase 2 data due by year-end Biotech 2050 Podcast. If oral versions of these drugs work, they reshape a huge slice of the immune-disease market.

Stocks on the Radar

Direction reflects the tone of this week's podcast and news commentary, not a recommendation.

Upcoming Catalysts (Next ~2 Weeks)

• September 18: Nuvalent (NVLNT) FDA decision on zidesamtinib, a lung-cancer drug; would be the company's first product, a genuinely make-or-break event.
• September 19: Ultragenyx (RARE) FDA decision on UX111, a gene therapy for the rare childhood disease Sanfilippo syndrome type A.
• September 21: Merck (MRK) FDA decision on expanding its pulmonary-hypertension drug Winrevair.
• September 22: Ionis (IONS) FDA decision on zilganersen for the rare Alexander disease.
• September 23–25: BioCentury Grand Rounds Europe (Amsterdam): a read on cross-border and China dealmaking momentum.
• September 26: Incyte (INCY) FDA decision on zilurgisertib for a rare bone disorder.
• September 28 – October 2: EASD, Milan: the year's biggest diabetes meeting and the single highest-impact event in this window, with next-generation obesity and diabetes data expected from Novo Nordisk and Eli Lilly.
• September 30: two clocks strike at once: Scholar Rock's (SRRK) FDA decision on its muscle drug apitegromab in spinal muscular atrophy, and the deadline for CMS to send final Medicare drug-price offers in the third negotiation round.
• September 29–30: BioTechX, Boston: AI-in-drug-discovery focus, with Lilly R&D executives.
• Late September / early Q4: binary readouts: Celldex (CLDX) in chronic hives, Kodiak Sciences (KOD) in wet age-related macular degeneration, and Fate Therapeutics (FATE) in lupus, each a single-result stock mover.
• No large-cap healthcare earnings land in the window; the next wave starts October 13 with UnitedHealth and Johnson & Johnson.

The Bottom Line

This was a week about where the next great drugs actually come from, and whether the market has correctly priced them.

The optimistic answer is thrilling: a personalized cancer vaccine that works, a first-ever drug for pancreatic cancer, obesity medicines that are learning to protect muscle instead of just melting weight. Money noticed, rotating out of tired AI trades and into a biotech sector that had spent years in the doghouse. But the smartest voices kept applying the same discipline: a breakthrough in the clinic is not the same as a breakthrough in the stock. As David Wehner put it about Moderna, the science is real and the future revenue is already in the price, two things that can both be true, and that can make a stock painful to own.

The more unsettling answer is geographic. Merck's most important pipeline drug came from China. A Chinese drug beat Keytruda in a head-to-head trial. Between a third and half of the world's experimental medicines now originate there, at half the cost and twice the speed. That is either the greatest shopping opportunity in pharma history or the beginning of the end of American dominance in the industry, and this week, serious people argued it's both.

Underneath the excitement, the plumbing is being tested. Insurers are pulling back on the obesity drugs everyone wanted, half of patients quit within a year, and a Medicare pricing deadline lands in twelve days. The heart-drug failures from earlier this month are still being dissected, with Amgen's and Lilly's versions the next dominoes to watch. For anyone following the space, the throughline is the same one that's held all quarter: the science has rarely been more exciting, but the market has stopped paying for excitement alone: it wants data it can hold, drugs that can be paid for, and a clear answer to who wins when the patents roll off.